Eli Lilly is laying the groundwork for an even bigger weight loss takeover. The company is preparing to put its obesity pill orforglipron up for regulatory review after the drug shined in a phase 3 study. With an average 10.5% weight loss, lower blood sugar levels and improved cardiometabolic health in patients with either obesity or Type 2 diabetes, Lilly has another potential gamechanger on its hands.

"With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting,” said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, in a company statement.

The news puts Lilly just behind its market rival Novo Nordisk, which has already submitted its own GLP-1 oral pill for FDA approval. But they’re not the only drugmakers developing alternative methods of delivery. The market is chock full of newcomers getting their foot in the door. Today, we’re catching up with one biopharma looking for a way into the booming obesity market with a GLP-1 implant.

Thanks for reading.